Results 171 to 180 of about 53,515 (238)

Inzidenz, Schweregrad und möglicher Pathomechanismus von Immuntherapie‐assoziiertem Pruritus bei Melanompatienten

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 11, Page 1566-1574, November 2026.
Zusammenfassung Hintergrund und Ziele Pruritus ist eine häufige immunvermittelte unerwünschte Wirkung (irAE) unter Therapie mit Checkpoint‐Inhibitoren (ICI) und beeinträchtigt die Lebensqualität der Patienten erheblich. In dieser Studie untersuchen wir die Häufigkeit, den Schweregrad und Therapieansätze von Pruritus bei Melanompatienten unter ICI ...
Andrea Roggo   +6 more
wiley   +1 more source

Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background & Aims The management of comorbidities has become increasingly relevant in unresectable hepatocellular carcinoma (uHCC) as immunotherapy prolongs survival. Atezolizumab plus bevacizumab (AB) is a standard first‐line option, but bevacizumab carries a risk of cardiovascular toxicities.
Bernardo Stefanini   +55 more
wiley   +1 more source

An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres

open access: yesMedical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs   +15 more
wiley   +1 more source

Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors. [PDF]

open access: yesESMO Gastrointest Oncol
Alsina M   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy